Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 30 ... in orthotopic liver tumor models comprised of both HCC- and colorectal cancer-derived cell lines. ALN-VSP was also shown to act on disseminated tumors outside of the liver. ... Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced new pre-clinical data from its ALN-VSP program presented at the ...
2009 NOV 30 ... the delivery of siRNAs in vivo into T-cells, although it can be used to target any cell type. The patent pending T3 Technology functions by conjugating an RNAi agent carrier to ... for HIV infection, recently entered into a collaborative research agreement with Bioo Therapeutics, a division of Bioo Scientific, to leverage their T3™ technology to facilitate the ...
2009 NOV 30 ... level of PI3K pathway activation in the presence of PTEN loss in a screen of solid tumor cell lines. In all cases CAL-120 blocked the PI3K pathway resulting in inhibition of tumor ... PI3K inhibitor, at the AACR-EORTC-NCI International Molecular Targets and Cancer Therapeutics Conference in Boston, Mass. The PI3K pathway is a target of significant ... Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase ...
2009 NOV 30 ... that argument and demonstrate how shielding lung cancer cells from opiates reduces cell proliferation, invasion and migration in both cell-culture and mouse models. ... The reports--to be presented November 18, 2009, at "Molecular Targets and Cancer Therapeutics," a joint meeting in Boston of the American Association for Cancer Research, the ...
2009 NOV 30 ... breast cancer reconstruction study, RESTORE 2. The study is evaluating the use of cell-enriched fat grafting to restore functional and cosmetic deformities in women who have ... Cytori Therapeutics (NASDAQ:CYTX) completed enrollment in a 70-patient, international breast cancer ...
2009 NOV 30 ... (PI3K). Activation of the PI3K pathway is a frequent event in human tumors, promoting cell proliferation, survival, and resistance to chemotherapy and radiotherapy. The pathway ... 18, 2009, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which is being held November 15-19 in Boston. XL147 is being developed with ... Exelixis, Inc. (Nasdaq:EXEL) reported interim data from an ongoing phase 1 dose-escalation trial of ...
2009 NOV 30 ... "Fate Therapeutics has made rapid progress in advancing its pipeline of Stem Cell Modulators and in establishing the leading industrialized platform for induced ... Fate Therapeutics, Inc. announced that it has completed a $30 million Series B financing led by OVP Venture ...
2009 NOV 30 ... for the indefinite replicative capacity of cancer cells that enables their malignant cell growth. Telomerase is absent or expressed only transiently at low levels in most normal ... at the 2009 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. This Phase I study of imetelstat as a single agent is one of six ...
2009 NOV 30 ... positive results garnered from Phase I testing in ICT-107, the Company's dendritic cell therapy for glioblastoma, which demonstrated an ability to significantly improve the ... ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a biotechnology company that is focused on the development of novel ...
2009 NOV 30 ... steroid that is an analog of a dihydrotestosterone metabolic pathway member, stimulates cell death (apoptosis) in hormone-dependent prostate tumors. Presenting the data is the lead ... prostate cancer or CRPC). Presented at the Molecular Targets and Cancer Therapeutics Conference, which is co-sponsored by the AACR, NCI and EORTC, the poster is titled: ... Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH), reported preliminary results of its ongoing Phase I/II clinical trial ...
2009 NOV 30 ... after a pandemic threat emerges. The Company has developed an integrated therapeutic T-cell vaccine platform which combines a proprietary vaccine antigen delivery technology with ... Ken Powell has joined the board as non-executive Chairman. Ken was formerly CEO of Arrow Therapeutics which he led to a successful trade sale to Astra-Zeneca in 2007. The Company also ...
2009 NOV 30 ... was assessed by using Boyden microchambers. The chemotactic index was used to evaluate cell migration. LTB4 was measured by a specific enzyme immunoassay. The contribution of LTB4 ... Immunoassay, Life Sciences This article was prepared by Respiratory Therapeutics Week editors from staff and other reports. Copyright 2009, Respiratory Therapeutics ...
2009 NOV 30 ... Carboplatin/Paclitaxel in Patients with Advanced Solid Cancers with Emphasis on Squamous Cell Carcinoma of the Head and Neck (SCCHN)." The investigators reported that ... cancers in a poster presentation at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference being held in Boston, Massachusetts. The poster presentation is entitled ... Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") announced updated results ...
2009 NOV 30 ... in Phase II clinical trials for the treatment of advanced breast cancer and non-small cell lung cancer. Peregrine's collaborators at UT Southwestern Medical Center, ... is an early confirmation of the potential of our anti-PS antibodies as broad-spectrum therapeutics for VHF," said Steven W. King, president and CEO of Peregrine. "They also reflect the ... Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) announced that researchers presented positive data on progress in its ...
2009 NOV 30 ... Congress The DigestScience Congress in Lille France will address the cutting edge of cell therapy in IBD. About Pluristem Pluristem is a clinical stage biotechnology company with ... Pluristem TherapeuticsInc. (NasdaqCM:PSTI) (DAX:PJT) announced that it will present three month follow-up data ...
2009 NOV 30 ... tissue of interest. This allele,was used to generate a model of germinal center B-cell lymphoma by activating SBase expression with an Aid-Cre allele. In a second approach, a ... According to a study from the United States, "Recent advances in cancer therapeutics stress the need for a better understanding of the molecular mechanisms driving tumor ...
2009 DEC 1 ... Journal of Virology, "Despite the susceptibility of dendritic cells (DCs) to human T-cell lymphotropic virus type 1 (HTLV-1) infection and the defined role of these cells in ... infection, thereby providing an attractive target for the development of antiretroviral therapeutics and microbicides." Jain and colleagues published their study in the ...
2009 NOV 30 ... one year and revealed the continuous outgrowth of adherent and proliferating primary cell populations." "Immunofluorescence staining of these human breast ... providing a reproducible screening platform to identify new biomarkers and to test new therapeutics in individual tumor samples." Hass and colleagues published the results of ...
2009 NOV 30 ... membrane potential and the pH gradient of Gram-positive bacteria, correlating well with cell death. Notably, in stark contrast to its parent molecule 3-oxo-dodecanoyl homoserine ... scaffold may also serve as a new lead compound for the development of antimicrobial therapeutics." Lowery and colleagues published their study in the Journal of the ...
